Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically documented AML, ALL, MDS, CML,~* Identification of haploidentical donor~* LVEF \> 45% corrected~* DLCO \> 50% predicted~* Serum Creatinine \<= 2 mg/dL~* Bilirubin \< 2 x ULN~* AST, ALT \< 2 x ULN~* Age ≤ 65 years~* Performance Status 0-1~Exclusion Criteria:~* Patients relapsing \<6 months after autologous SCT are not eligible.~* Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection~* No HIV disease~* Non-pregnant and non-nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Alloreactive NK cell infusion (Type: EXPERIMENTAL): Escalating doses of alloreactive NK cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).